HELP
CYBIN INC.
$4.29
+0.94%
$214.7M
No data for this timeframe.
Vol
Market Cap$214.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders24 funds
Inst. Value$17.3M
Inst. Activity0 buys / 4 sells
Reddit Sentiment70° Bullish
SEC Reports6
Press Releases4
Recent Activity
Jun 1, 2026
SEC
Helus Pharma (Cybin Inc.) announced its interim CEO will participate in a fireside chat at the Jefferies Global Healthca
6-K — Impact 2/10
Apr 30, 2026
SEC
Helus Pharma (Cybin Inc.) filed a 6-K announcing that Interim CEO Eric So will speak on a panel at the Milken Institute
6-K — Impact 2/10
Apr 28, 2026
SEC
Helus Pharma (Cybin Inc.) announced a collaboration with TARA Mind to support recruitment for its HLP003 Phase 3 MDD tri
6-K — Impact 3/10
Inst.
PEAK6 LLC — NEAR_EXIT
62,597 shares ($300.5K)
Inst.
Point72 Asset Management, L.P. — NEAR_EXIT
19,684 shares ($94.5K)
Jun 11, 2026
other
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
<p align="justify">NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus Pharma<sup>TM</su
Apr 30, 2026
Press
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major dep
Impact 3/10
Apr 20, 2026
Press
Helus Pharma welcomed a White House Executive Order aimed at accelerating research, regulatory pathways, and patient acc
Impact 4/10
Price Targets
$42.94
+900.9% upside
Strong Buy
Current $4.29
Low $7.89
Median $45.01
High $92.32
8 analysts
$7.89
$92.32
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 13, 2026 | TD Cowen | INITIATE | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.13 ▼ -43.4% | $-1.47 — $-0.86 | 22% YoY | 5 |
| Next Q | $-1.14 ▼ -8.9% | $-1.55 — $-0.92 | -18% YoY | 4 |
| Current FY | $-5.24 ▼ -22.2% | $-5.75 — $-4.90 | 6% YoY | 5 |
| Next FY | $-4.40 ▼ -9.1% | $-5.55 — $-3.63 | 16% YoY | 4 |
Latest Reports
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) announced its interim CEO will participate in a fireside chat at the Jefferies Global Healthca
Jun 1, 2026
NEUTRAL
Press
3/10
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major dep
Apr 30, 2026
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) filed a 6-K announcing that Interim CEO Eric So will speak on a panel at the Milken Institute
Apr 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $4.9M | DOUBLED |
| CITADEL ADVISORS LLC | $4.2M | — |
| ADAGE CAPITAL PARTNERS GP, | $3.4M | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.1M | — |
| ROYCE & ASSOCIATES LP | $744.2K | — |
Reddit Sentiment
70°
Bullish
Bearish
Neutral
Bullish
24 institutional holders with $17.3M total value (3,791,531 shares) as of 2026-Q1. Top holders: MORGAN, CITADEL, ADAGE. Net selling activity: 4 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 1,025,318 | $4.9M | 28.5% | DOUBLED +470.9% |
| 2 | CITADEL ADVISORS LLC | 877,347 | $4.2M | 24.4% | — |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 700,000 | $3.4M | 19.4% | — |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 223,500 | $1.1M | 6.2% | — |
| 5 | ROYCE & ASSOCIATES LP | 155,050 | $744.2K | 4.3% | — |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 147,925 | $710.0K | 4.1% | — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 126,900 | $609.1K | 3.5% | — |
| 8 | GOLDMAN SACHS GROUP INC | 90,000 | $432.0K | 2.5% | — |
| 9 | PEAK6 LLC | 62,597 | $300.5K | 1.7% | NEAR_EXIT -77.9% |
| 10 | GOLDMAN SACHS GROUP INC | 51,588 | $247.6K | 1.4% | — |
| 11 | ROYAL BANK OF CANADA | 31,592 | $151.0K | 0.9% | DOUBLED +346.0% |
| 12 | BlackRock, Inc. | 29,126 | $139.8K | 0.8% | NEAR_EXIT -82.0% |
| 13 | CITADEL ADVISORS LLC | 24,200 | $116.2K | 0.7% | — |
| 14 | Point72 Asset Management, L.P. | 19,684 | $94.5K | 0.5% | NEAR_EXIT -99.6% |
| 15 | CITADEL ADVISORS LLC | 14,100 | $67.7K | 0.4% | — |
| 16 | Centiva Capital, LP | 10,000 | $48.0K | 0.3% | — |
| 17 | CITIGROUP INC | 5,952 | $28.7K | 0.2% | — |
| 18 | NATIONAL BANK OF CANADA /FI/ | 5,132 | $17.4K | 0.1% | DOUBLED +3546.5% |
| 19 | GROUP ONE TRADING LLC | 3,462 | $16.6K | 0.1% | TRIM -67.7% |
| 20 | BARCLAYS PLC | 862 | $4.1K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| PEAK6 LLC | NEAR_EXIT | 283,507 | 62,597 | -77.9% | $300.5K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 4,432,559 | 19,684 | -99.6% | $94.5K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 10,725 | 3,462 | -67.7% | $16.6K | 2026-Q1 |
| TD Waterhouse Canada Inc. | NEAR_EXIT | 2,033 | 117 | -94.2% | $580.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 1,239,629 | 4,432,559 | +257.6% | $36.3M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 227,661 | 1,299,756 | +470.9% | $10.6M | 2025-Q4 |
| PEAK6 LLC | DOUBLED | 82,708 | 283,507 | +242.8% | $2.8M | 2025-Q4 |
| BlackRock, Inc. | NEAR_EXIT | 141,320 | 25,403 | -82.0% | $207.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 63,056 | 4,248 | -93.3% | $34.7K | 2025-Q4 |
| TD Waterhouse Canada Inc. | TRIM | 2,753 | 2,033 | -26.2% | $16.4K | 2025-Q4 |
| Allworth Financial LP | TRIM | 46 | 20 | -56.5% | $164.00 | 2025-Q4 |
| UBS Group AG | ADD | 179,443 | 303,740 | +69.3% | $1.8M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 22,821 | 227,661 | +897.6% | $1.3M | 2025-Q3 |
| PEAK6 LLC | DOUBLED | 26,284 | 82,708 | +214.7% | $487.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 29,443 | 63,056 | +114.2% | $371.4K | 2025-Q3 |
| Point72 Asset Management, L.P. | ADD | 817,965 | 1,606,317 | +96.4% | $13.5M | 2025-Q2 |
| Allworth Financial LP | ADD | 26 | 46 | +76.9% | $386.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,751 | 177,592 | +10042.3% | $1.1M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 10,642 | 46,526 | +337.2% | $295.0K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,195 | 17,653 | +1377.2% | $111.9K | 2025-Q1 |
| ROYAL BANK OF CANADA | DOUBLED | 3,030 | 13,515 | +346.0% | $86.0K | 2025-Q1 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 144 | 5,251 | +3546.5% | $23.1K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,809 | 10,642 | +278.9% | $93.9K | 2024-Q4 |
| ROYAL BANK OF CANADA | DOUBLED | 1,284 | 3,030 | +136.0% | $27.0K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 10,523 | 1,751 | -83.4% | $15.4K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 2.8/10.
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) announced its interim CEO will participate in a fireside chat at the Jeffe
Jun 1, 2026
NEUTRAL
6-K
2/10
Helus Pharma (Cybin Inc.) filed a 6-K announcing that Interim CEO Eric So will speak on a panel at t
Apr 30, 2026
NEUTRAL
6-K
3/10
Helus Pharma (Cybin Inc.) announced a collaboration with TARA Mind to support recruitment for its HL
Apr 28, 2026
NEUTRAL
6-K
3/10
Cybin Inc. (HELP) issued a press release through its commercial entity Helus Pharma welcoming a Whit
Apr 20, 2026
NEUTRAL
6-K
4/10
Cybin Inc. (HELP) announced the immediate departure of CEO Michael Cola and the appointment of co-fo
Apr 20, 2026
NEUTRAL
6-K
3/10
Cybin Inc. (HELP) announced the appointment of Dr. Ken Kramer as Senior Vice President, Medical Affa
Apr 16, 2026
NEUTRAL
3/10
Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003
Apr 30, 2026
NEUTRAL
4/10
Helus Pharma welcomed a White House Executive Order aimed at accelerating research, regulatory pathw
Apr 20, 2026
NEUTRAL
3/10
Helus Pharma announced the appointment of Dr. Ken Kramer as Senior Vice President, Medical Affairs,
Apr 16, 2026
BULLISH
8/10
Helus Pharma announced positive topline results from a Phase 2 signal detection study of HLP004, an
Mar 5, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$42.94 mean target
+900.9% upside
Strong Buy (1.00)
$7.89 Low
$92.32 High
| Metric | Value |
|---|---|
| Current Price | $4.29 |
| Target Low | $7.89 |
| Target Mean | $42.94 |
| Target Median | $45.01 |
| Target High | $92.32 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-1.13 | $-1.47 | $-0.86 | 22.4% | -43.4% | 1↑ 2↓ | $0.0B | 0.0% | 5 |
| Next Q 2026-06-30 |
$-1.14 | $-1.55 | $-0.92 | -17.9% | -8.9% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-03-31 |
$-5.24 | $-5.75 | $-4.90 | 6.3% | -22.2% | 0↑ 2↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-03-31 |
$-4.40 | $-5.55 | $-3.63 | 16.0% | -9.1% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.133 | |
| 7d ago | $-0.969 | -0.164 |
| 30d ago | $-0.790 | -0.343 |
| 60d ago | $-0.790 | -0.343 |
| 90d ago | $-0.790 | -0.343 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 13, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
70°
Bullish
Bearish
Neutral
Bullish
29 mentions
18 bullish
5 bearish
28 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 29, 2026 | 2 | 33° Cool | 0 | 2 | 2 |
| Mar 29, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 3, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
What do we think about Cybin?(HELP)
▲ 1
💬 0
⚡ 0.5
Don’t invest in Microcaps
▲ 1
💬 0
⚡ 0.5
Jun 11, 2026
other
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
<p align="justify">NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus Pharma<sup>TM</sup> (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stag
Apr 30, 2026
contract
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
<p align="justify">NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helu
Apr 30, 2026
other
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
<p align="justify">NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceu
Apr 28, 2026
contract
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
<p align="justify">NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmac
Apr 23, 2026
other
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
<p align="justify">NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceu
Apr 20, 2026
fda
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
<p align="justify">NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceu
Apr 16, 2026
leadership
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
<p align="justify">NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus Pharma<sup>TM</sup> (Nasdaq: HELP) (Cboe CA: HELP), a clinical sta
Mar 12, 2026
other
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
<p align="justify">NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus Pharma<sup>TM</sup> (Nasdaq: HELP) (Cboe CA: HELP), a clinical sta
Mar 6, 2026
short_interest
FTD: HELP — 255,244 shares ($1.4M) failed to deliver
Settlement: 20260306, Price: $5.64, FTD Value: $1,439,576.16, CYBIN INC COM NEW (CANADA)
Mar 5, 2026
fda
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
<p><strong>Figure 1</strong></p>